3-碘-1-甲基-1H-吡唑并[4,3-b]吡啶 | 1354954-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 3-碘-1-甲基-1H-吡唑并[4,3-b]吡啶
• 英文名称: 3-iodo-1-methyl-1H-pyrazolo[4,3-b]pyridine
• 英文别名: 3-iodo-1-methylpyrazolo[4,3-b]pyridine
• CAS: 1354954-40-7
• 化学式: C₇H₆IN₃
• mdl: MFCD20441621
• 分子量: 259.049
• InChiKey: NXNLWRAKHMLTGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(叔丁氧基羰基氨基)吡啶-4-硼酸频那醇酯 、 3-碘-1-甲基-1H-吡唑并[4,3-b]吡啶 在 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

  摘要：

  公开号：

  EP3345906B1

文献信息

• [EN] HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORGAMMAT INHIBITORS AND USES THEREOF<br/>[FR] ACIDES BENZOÏQUES À SUBSTITUTION HÉTÉROARYLE EN TANT QU'INHIBITEURS DE RORGAMMAT ET LEURS UTILISATIONS
  申请人：MERCK SHARP & DOHME

  公开号：WO2017075185A1

  公开（公告）日：2017-05-04

  The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

  本发明涉及式I化合物及其可药用的盐。这类化合物可用于治疗RORgammaT介导的疾病或状况。
• [EN] MULTIVALENT RAS BINDING COMPOUNDS<br/>[FR] COMPOSÉS DE LIAISON RAS MULTIVALENTS
  申请人：KYRAS THERAPEUTICS INC

  公开号：WO2017096045A1

  公开（公告）日：2017-06-08

  Described herein are compounds that modulate Ras signaling, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with altered Ras signaling. Further described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds and methods of using such compounds in the treatment of cell proliferative disorders, including cancer.

  本文描述了调节Ras信号传导的化合物，制备这种化合物的方法，包含这种化合物的药物组合物和药物，以及使用这种化合物治疗与改变的Ras信号传导相关的疾病、疾病或紊乱的方法。此外，本文还描述了化合物、制备这种化合物的方法、包含这种化合物的药物组合物和药物，并且使用这种化合物治疗细胞增殖紊乱，包括癌症的方法。
• 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10196354B2

  公开（公告）日：2019-02-05

  The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

  本发明涉及根据式 I（式 I）的化合物及其药学上可接受的盐或溶液。此类化合物可用于治疗 RORgammaT 介导的疾病或病症。
• 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof
  申请人：Wuxi Shuangliang Biotechnology Co., Ltd.

  公开号：US10377747B2

  公开（公告）日：2019-08-13

  The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth factor receptor, for example the L858R activating mutant, the delE746_A750 mutant, the Exonl9 deletion activating mutant, and the T790M resistance mutant, so as to be used for treatment and prevention of diseases and medical conditions. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may be used for treatment and prevention of cancer. The present disclosure also relates to a pharmaceutical composition comprising 2-arylamino pyridine, pyrimidine, or triazine derivatives, intermediates useful in the manufacture of 2-arylamino pyridine, pyrimidine, or triazine derivatives, and to methods of treatment of diseases mediated by various different forms of EGFR using 2-arylamino pyridine, pyrimidine, or triazine derivatives.

  本公开涉及 2-芳基氨基吡啶、嘧啶或三嗪衍生物及其制备方法和用途。2-芳基氨基吡啶、嘧啶或三嗪衍生物可作用于表皮生长因子受体的某些突变形式，例如 L858R 激活突变体、delE746_A750 突变体、Exonl9 缺失激活突变体和 T790M 抗性突变体，从而可用于治疗和预防疾病和病症。2-芳基氨基吡啶、嘧啶或三嗪衍生物可用于治疗和预防癌症。本公开还涉及包含 2-芳基氨基吡啶、嘧啶或三嗪衍生物的药物组合物，用于制造 2-芳基氨基吡啶、嘧啶或三嗪衍生物的中间体，以及使用 2-芳基氨基吡啶、嘧啶或三嗪衍生物治疗由各种不同形式的表皮生长因子受体介导的疾病的方法。
• 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20180022701A1

  公开（公告）日：2018-01-25

  The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.